Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Starpharma Holdings Limited ( (AU:SPL) ) has provided an update.
Starpharma Holdings Limited has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year under the Australian Federal Government’s program. This incentive is crucial for Starpharma as it continues to invest in high-impact R&D programs, strengthening its position in the global biotechnology sector and supporting the advancement of its dendrimer technology towards commercialization and global patient benefit.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company with over two decades of experience in advancing dendrimer technology from the lab to the patient. The company focuses on improving health outcomes for patients with significant illnesses, such as cancer, through its unique dendrimer technology. Starpharma’s portfolio includes clinical-stage DEP® assets, preclinical radiopharmaceutical assets, research collaborations, and commercially marketed over-the-counter products.
Average Trading Volume: 397,361
Technical Sentiment Signal: Hold
Current Market Cap: A$52.28M
For detailed information about SPL stock, go to TipRanks’ Stock Analysis page.